Horizon Pharma plc Receives Positive CHMP Opinion for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Horizon Pharma plc Receives Positive CHMP Opinion for RAVICTI(R) (Glycerol Phenylbutyrate) Oral Liquid for the Treatment of Urea Cycle Disorders in Patients Greater Than Two Months of Age

DUBLIN, IRELAND--(Marketwired - Sep 25, 2015) - Horizon Pharma plc ( NASDAQ : HZNP ), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, and its affiliate Horizon Therapeutics Limited today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion at its plenary monthly meeting in September recommending  a centralized marketing authorization for RAVICTI® (glycerol phenylbutyrate) Oral Liquid for use as an adjunctive therapy for chronic management of adult and pediatric patients greater than two months of age with Urea Cycle Disorders (UCDs).  A full summary of the opinion can be found here .  Detailed recommendations for the use of RAVICTI will be described in the summary of product characteristics (SmPC), which will be published in the European public assessment report (EPAR) and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The adopted positive opinion will be considered by the European Commission for a binding decision to be issued for the granting of a centralized marketing authorization within 60 to 90 days from the date of adoption of the opinion.

RAVICTI was approved by the U.S. Food and Drug Administration (FDA) in February 2013 for chronic management of adult and pediatric patients greater than or equal to 2 years of age with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. The European Centralized Marketing Authorization Application for RAVICTI included additional data to support an assessment of safety and efficacy in patients greater than two months of age.

"The adopted CHMP positive opinion marks an important step in bringing this medicine to those in the European Union and European Economic Area with Urea Cycle Disorders who are in need of additional treatment options," said Timothy P. Walbert, chairman, president and chief executive officer, Horizon Pharma plc. "If not managed appropriately, symptoms caused by high ammonia levels in the blood can significantly impact the body and brain. RAVICTI, pending a confirmatory binding decision by the European Commission, will cover a broader range of Urea Cycle Disorders compared to currently marketed medicines and will be easier for patients to use.

"The positive opinion represents a key milestone in our strategy to expand and build, organically and through acquisition, our infrastructure in Europe and the rest of the world. Based on our ability to rapidly execute and navigate the CHMP process since the Hyperion acquisition close, we have accelerated the timeline for our strategy in Europe," Walbert continued.

UCDs are inherited metabolic diseases caused by a deficiency of one of the enzymes or transporters necessary for the conversion of ammonia to urea, which results in heightened levels of ammonia in the bloodstream. UCD patients may experience episodes where they get symptoms from the ammonia in their blood being excessively high -- called hyperammonemic crises -- which may result in irreversible brain damage, coma or death. UCD symptoms may first occur at any age depending on the severity of the disorder, with more severe defects presenting earlier in life.

About RAVICTI RAVICTI is currently indicated for use in the United States as a nitrogen-binding agent for chronic management of adult and pediatric patients greater or equal to 2 years of age with UCDs who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline and protein-free calorie supplements).

Important Safety Information

LIMITATIONS OF USE:

  • RAVICTI is not indicated for the treatment of acute hyperammonemia in patients with UCDs because more rapidly acting interventions are essential to reduce plasma ammonia levels
  • The safety and efficacy of RAVICTI for the treatment of N-acetylglutamate synthase (NAGS) deficiency has not been established
  • The use of RAVICTI in patients < 2 months of age is contraindicated

CONTRAINDICATIONS:

  • In patients less than 2 months of age
  • In patients who develop or have known hypersensitivity to phenylbutyrate

WARNINGS AND PRECAUTIONS:

  • Phenylacetate (PAA), the major metabolite of RAVICTI, may be toxic at levels ≥ 500 µg/mL. Reduce RAVICTI dosage if symptoms of neurotoxicity, including vomiting, nausea, headache, somnolence, confusion, or sleepiness are present in the absence of high ammonia or other intercurrent illnesses.
  • Low or absent pancreatic enzymes or intestinal disease resulting in fat malabsorption may result in reduced or absent digestion of RAVICTI and/or absorption of phenylbutyrate and reduced control of plasma ammonia. Monitor ammonia levels closely.
  • RAVICTI should be used with caution in patients who are pregnant or planning to become pregnant. Based on animal data it may cause fetal harm. A voluntary patient registry will include evaluation of pregnancy outcomes in patients with UCDs. For more information regarding the registry program, visit www.ucdregistry.com or call 1-855-823-2592
  • Caution should be exercised when administering RAVICTI to nursing mothers, as breastfeeding is not recommended with maternal use of RAVICTI. It is not known whether RAVICTI or its metabolites are present in breast milk

ADVERSE REACTIONS:

  • Adverse reactions occurring in ≥ 10% of adult patients during short-term treatment (n=44, 4 weeks) with RAVICTI were diarrhea, flatulence and headache.
  • Adverse reactions occurring in ≥ 10% of adult patients during long-term treatment (n=51, 12 months) with RAVICTI were nausea, vomiting, diarrhea, decreased appetite, hyperammonemia, dizziness, headache and fatigue.
  • Adverse events occurring in ≥ 10% of pediatric patients during long-term treatment (n=26, 12 months) with RAVICTI were upper abdominal pain, rash, nausea, vomiting, diarrhea, decreased appetite, hyperammonemia and headache

DRUG INTERACTIONS:

  • Corticosteroids, valproic acid or haloperidol: May increase plasma ammonia level. Monitor ammonia levels closely
  • Probenecid: May affect renal excretion of metabolites of RAVICTI, including PAGN and PAA

About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com . Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Forward-Looking Statements This press release contains forward-looking statements, including statements regarding the timing of regulatory events related to potential marketing authorization for RAVICTI, the potential of RAVICTI to treat UCD patients and Horizon Pharma's strategy and plans to build its infrastructure in Europe and the rest of the world. These forward-looking statements are based on management expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors. These factors include risks regarding whether RAVICTI is ultimately approved for marketing in Europe, the fact that a positive CHMP opinion does not guarantee such approval, whether, if approved for marketing, Horizon Pharma will be able to obtain adequate pricing and reimbursement and successfully commercialize RAVICTI in Europe, whether Horizon Pharma will be able to successfully execute its growth strategy outside of the United States, and other factors described in Horizon's filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in those filings. Forward-looking statements speak only as of the date of this press release and Horizon does not undertake any obligation to update or revise these statements, except as may be required by law.

Contacts: Investors: John Thomas Executive Vice President, Strategy and Investor Relations Investor-relations@horizonpharma.com Tina Ventura Vice President, Investor Relations Investor-relations@horizonpharma.com U.S. Media Contact: Geoff Curtis Group Vice President, Corporate Communications gcurtis@horizonpharma.com Ireland Media Contact: Ray Gordon Gordon MRM ray@gordonmrm.ie

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 181

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
AutoShop Answers Extends 2027 Training Into Fridays

Updated Category News Views 83

A repair bay can hum all day while the back office quietly bleeds profit. That unglamorous reality is why AutoShop Answers adding nine Friday specialty classes to its 2027 Key2Key Weekend calendar deserves a closer look. This is not a new tool chest or some vague motivational roadshow; it is an attempt to give independent shop owners an extra day to work on the pieces...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 118

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 473

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 102

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 372

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 66

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 221

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading

Top 5 Most Recently Viewed Articles

GreenCore Solutions Unveils Innovative Partnership for Eco-Friendly Diapers

Updated Category News Views 165

New Collaboration to Enhance Retail Visibility GreenCore Solutions Corp., a frontrunner in eco-friendly diaper innovation, has joined forces with Emerson TEN OÜ. This strategic partnership aims to elevate the visibility of GreenCore's TreeFree Diaper products across European retail settings, including grocery and convenience stores. Transforming the Shopping Experience...

Continue Reading
Oman's Stock Exchange Sees Unprecedented Growth to $8.45 Billion

Updated Category News Views 339

Oman's Muscat Stock Exchange Achieves Significant Trading Growth Recent reports indicate that Oman's Muscat Stock Exchange (MSX) has experienced a remarkable performance, marking the highest trading values seen in many years. Fueled by reforms initiated by the Oman Investment Authority (OIA), the exchange has recorded an impressive trading value of approximately USD 8.45...

Continue Reading
Gloo Partners with Servant to Transform Faith-Based Organizations

Updated Category News Views 409

Gloo's Strategic Investment in Servant In an exciting new development for the faith ecosystem, Gloo has announced a significant investment in Servant, a leading consultancy dedicated to assisting organizations in their growth and digital transformation efforts. This partnership highlights Gloo's commitment to enhancing the capabilities of various faith-based...

Continue Reading
Movate Enhances AI Solutions by Acquiring Prescience for Growth

Updated Category News Views 332

Acquisition Announcement by Movate Movate, a prominent provider of digital technology services, has made a strategic move by acquiring Prescience, a key player in the field of data science and artificial intelligence. This acquisition marks a significant step for Movate as it aims to embed AI deeply into its service offerings. Through this merger, Movate seeks to enable...

Continue Reading
Stellantis Faces Rising Tensions as UAW Considers Strikes Ahead

Updated Category News Views 88

Tensions Rise Between Stellantis and UAW Stellantis, the French-Italian automotive powerhouse, is facing growing scrutiny as the United Auto Workers (UAW) union gears up for potential strikes due to allegations of contract violations. This situation emerges almost a year after a major national walkout, which led to significant losses for the Detroit Three automakers and...

Continue Reading